Erratum: A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol (Menopause (2016) 23 (506-510) DOI: 10.1097/GME.0000000000000592)
Menopause, ISSN: 1530-0374, Vol: 23, Issue: 9, Page: 1052-null
2016
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Correction Description
In the article appearing in volume 23, pages 506-510, of Menopause, entitled ‘‘A randomized, double-blind, placebocontrolled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol,’’ there was an error. On page 506, several conflict of interest disclosures were not published for the article. In the case of author Brian A. Bernick, MD, disclosures were made prior to the article’s publication but, inadvertently, were not published with the final article. They are: Dr Bernick is an employee/board member of TherapeuticsMD and has stock and options with TherapeuticsMD. The following authors did not fully disclose conflicts of interest as required by the journal and would like to make the following disclosures: The authors Julia M. Amadio and Sebastian Mirkin, MD are employed by TherapeuticsMD as noted in the published article, and they also disclose that they own stock options in the company. The authors regret their oversight.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85122894072&origin=inward; http://dx.doi.org/10.1097/gme.0000000000000728; http://www.ncbi.nlm.nih.gov/pubmed/27552336; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042192-201609000-00017; https://journals.lww.com/00042192-201609000-00017
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know